ACU Q2 2026 Earnings: Acme United Surpasses Estimates on MyMedic Acquisition and Margin Recovery

• Acme United Corporation (ACU) reported Q2 2026 earnings per share of $1.22, significantly exceeding analyst estimates of $0.81, driven by strong organic growth and acquisition contributions.
• Revenue reached $62.7 million, beating the $58.1 million forecast, with sales increasing 16% year-over-year as the company transitions to lower-cost inventory to offset tariff pressures.
• The stock surged nearly 12% following the earnings release, trading near a 52-week high, though analyst consensus remains mixed with a Buy rating from Freedom Capital Markets suggesting downside from current levels.
• Strategic retail expansion is underway for BC3 Technologies' SEAL Hemostatic Wound Spray, marking first entry into brick-and-mortar retail via the Army & Air Force Exchange Service (AAFES).
• Management anticipates continued margin recovery through the end of the year, though elevated SG&A expenses and uneven geographic performance remain key investor risks.

Acme United Corporation delivered a robust financial performance for the second quarter of 2026, firmly surpassing Wall Street expectations across both top-line and bottom-line metrics. The company reported earnings per share of $1.22, a substantial outperformance against the consensus estimate of $0.81. This strong showing was mirrored in revenue, which hit $62.7 million compared to the projected $58.1 million. The market reacted immediately to the positive data, with shares surging nearly 12% to trade near a 52-week high of $51.88 following the announcement.

The growth trajectory was fueled by a combination of strategic acquisitions and underlying operational improvements. Total sales increased by 16% year-over-year, a figure significantly bolstered by the integration of MyMedic. When excluding the impacts of acquisitions, the company still demonstrated healthy organic growth of 8%. This dual engine of growth has allowed Acme United to not only expand its top line but also improve its profitability margins. Gross margins expanded to 42.6% from 41.0% in the prior year period, reflecting improved operational efficiency and cost management strategies implemented by the leadership team.

How Are Strategic Acquisitions Driving Revenue Growth?

A central pillar of Acme United's recent strategy has been the integration of acquired assets to diversify revenue streams and expand market reach. The MyMedic acquisition has been particularly instrumental in driving the 16% year-over-year sales increase. Management, led by CEO Johnsen, has highlighted ongoing integration efforts with a strategic focus on expanding distribution channels beyond direct-to-consumer models into mass retail environments. This shift is designed to capture a broader consumer base and increase brand visibility in traditional retail settings.

In parallel, the company is leveraging its distribution network to support portfolio companies like BC3 Technologies in achieving significant retail milestones. BC3 Technologies recently announced the retail availability of its flagship SEAL Hemostatic Wound Spray at 77 Army & Air Force Exchange Service (AAFES) locations. This partnership marks BC3's first entry into brick-and-mortar retail, utilizing Acme United's established distribution relationships. The rollout, which began in August 2026, targets major U.S. military installations such as Fort Bragg and Fort Campbell, as well as overseas locations in Okinawa, Japan. This expansion aligns with BC3's strategy to make advanced bleeding-control technology accessible to military personnel, their families, and the general public.

These strategic moves are expected to contribute to strong profitability in the fourth quarter, driven by seasonal demand patterns and the broadened distribution footprint. The integration of MyMedic into mass retail channels represents a critical step in realizing the full synergistic potential of the acquisition, potentially unlocking new revenue streams beyond the initial direct-to-consumer phase.

What Are the Margin Outlook and Key Investor Risks?

Looking ahead, Acme United's management projects continued margin recovery as the company navigates external economic headwinds. A primary focus is the transition of inventory, where higher-tariff stock is being systematically replaced by lower-cost inventory through the end of the year. This operational adjustment is expected to help mitigate tariff-related pressures and sustain the gross margin expansion observed in Q2. The company's low beta of 0.25x suggests a relatively stable stock performance relative to the broader market, which may appeal to conservative investors seeking steady returns.

Despite the positive outlook, investors are advised to monitor several key risks that could impact future performance. Selling, general, and administrative (SG&A) expenses remain elevated at 32% of sales, which could potentially pressure net income if not managed effectively. Additionally, the company faces ongoing challenges from tariff and freight costs, which may fluctuate and impact operational expenses. Currency fluctuations also pose a risk, particularly given the company's exposure to international markets.

Geographic performance has been uneven, with Canada lagging behind other markets, highlighting the need for careful regional management. Analyst sentiment reflects a mix of optimism and caution; while Freedom Capital Markets maintains a Buy rating with a price target of $53, this target implies a downside of approximately 13.61% from recent trading levels. The next earnings release is scheduled for October 20, 2026, with an estimated EPS of $0.67, providing a near-term benchmark for investors to assess the sustainability of the current growth trajectory.